Literature DB >> 23570142

An improved understanding of neuropathic pain.

Troels S Jensen1.   

Abstract

Neuropathic pain represents a series of relatively uncommon chronic pain conditions, caused by lesions or dysfunctions of peripheral or central afferent pathways in the nervous system. The symptoms and signs of neuropathic pain can all be explained by a neuronal hyperexcitability at the site of the nerve lesion, which subsequently and in a dynamic fashion recruits more central sites. The manifestations of such neuronal hyperexcitability are therefore rather similar, irrespective of the causes or sites of the lesions. The key findings in neuropathic pain are: (a) pain in an area with sensory loss; (b) positive sensory symptoms such as dysesthaesia and allodynia in the injured area, where sensory discrimination is abolished; and (c) an abnormal sympathetic activity. Our understanding of the mechanisms underlying neuronal hyperexcitability has increased dramatically within the last decade, and accordingly, it has been suggested that pain be classified according to a mechanism-based approach. The challenge for an improved understanding of neuropathic pain--which is the key for better treatment--lies in elucidating the relationships between symptoms, signs, aetiology, anatomical lesions, and underlying mechanisms. At present, this is not a trivial task.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 23570142     DOI: 10.1016/s1090-3801(02)90002-9

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  2 in total

1.  Nerve injury induced activation of fast-conducting high threshold mechanoreceptors predicts non-reflexive pain related behavior.

Authors:  M Danilo Boada; Thomas J Martin; Douglas G Ririe
Journal:  Neurosci Lett       Date:  2016-08-17       Impact factor: 3.046

2.  Differential drug effects on spontaneous and evoked pain behavior in a model of trigeminal neuropathic pain.

Authors:  K Deseure; G H Hans
Journal:  J Pain Res       Date:  2017-01-27       Impact factor: 3.133

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.